Gonzalez CF, Londoño AM, Cortes CI. Guía de práctica clínica para el tratamiento de la psoriasis en Colombia. Rev Asoc Colomb Dermatol. 2018;26(Suppl. 1):1- 256.

Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. ExtoBritish Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628- 36.

https://doi.org/10.1111/bjd.15665

Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-90.

https://doi.org/10.1111/jdv.14114

Amatore F, Villani AP, Tauber M, et al. Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-tosevere psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-83.

https://doi.org/10.1111/jdv.15340

Menter A, Strober BE, Kaplan DH, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-72.

https://doi.org/10.1016/j.jaad.2018.11.057

Strober BE, van der Walt JM, Armstrong AW, et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb). 2019;9(1):5-18.

https://doi.org/10.1007/s13555-018-0279-5

Pathirana D, Ormerod AD, Saiag P, et al. European S3- guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1-70.

Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.

https://doi.org/10.1007/s00403-010-1080-1

Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47-55.

https://doi.org/10.3899/jrheum.140102

Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2019. pii: S1473-3099(19)30575-4. doi: 10.1016/S1473- 3099(19)30575-4.

Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033-42.

https://doi.org/10.1111/bjd.15706

Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824-830.

https://doi.org/10.1016/j.jaad.2018.05.032

Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-61.

https://doi.org/10.1016/S0140-6736(18)31713-6

Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448-59.

https://doi.org/10.1016/j.clindermatol.2007.10.026

Raposo I, Torres T. Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. Am J Clin Dermatol. 2016;17(4):349-58.

https://doi.org/10.1007/s40257-016-0191-7

Reynolds KA, Pithadia DJ, Lee EB, et al. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatolog Treat. 2019;12:1-7. doi:10.1080/0 9546634.2019.1689228.

https://doi.org/10.1080/09546634.2019.1689228

Ramirez-Fort MK, Levin AA, Au SC, et al. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S63-70.

Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an antiinterleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdraw al and retreatment: Results from the phase III, doubleblind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418- 31.

https://doi.org/10.1016/j.jaad.2016.11.042

Hendrix N, Ollendorf DA, Chapman RH, et al. CostEffectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. J Manag Care Spec Pharm. 2018;24(12):1210-17.

https://doi.org/10.18553/jmcp.2018.24.12.1210

Castro-Ayarza JR, Gonzalez CF, Velasquez-Lopera MM. Actualización en biosimilares: una reflexión sobre la reglamentación en Colombia de los medicamentos biológicos y biosimilares. Rev Asoc Colomb Dermatol. 2015;23(1):23-9.

https://doi.org/10.29176/2590843X.287

De la Cruz C, de Carvalho AV, Dorantes GL, et al. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. J Dermatol. 2017;44(1):3-12.

https://doi.org/10.1111/1346-8138.13512

Pink AE, Smith CH. Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists. Br J Dermatol. 2017;177(1):7-8.

https://doi.org/10.1111/bjd.15645